Page 267 - 73_04

VOL. 73 (4), 1047-1078, 2007 DESARROLLO DE VACUNAS CONTRA EL VIH/SIDA

(19) TARTAGLIA, J.; PERKUS, M.E.; TAYLOR, J.; NORTON, E.K.; AUDONNET, J.C.; COX, W.I.
(20) ET AL. (1992) NYVAC: a highly attenuated strain of vaccinia virus. Virology.
188 (1): 217-32.
(21) NAJERA, J.L.; GOMEZ, C.E.; DOMINGO-GIL, E.; GHERARDI, M.M. AND ESTEBAN, M.
(2006) Cellular and biochemical differences between two attenuated poxvirus
(22) vaccine candidates (MVA and NYVAC) and role of the C7L gene. J. Virol. 80
(12): 6033-47.
(23) GALLEGO-GOMEZ, J.C.; RISCO, C.; RODRIGUEZ, D.; CABEZAS, P.; GUERRA, S.; CARRAS-
(24) COSA, J.L. ET AL. (2003) Differences in virus-induced cell morphology and in
virus maturation between MVA and other strains (WR, Ankara, and NYCBH)
(25) of vaccinia virus in infected human cells. J. Virol. 77 (19): 10606-22.
GUERRA, S.; LOPEZ-FERNANDEZ, L.A.; CONDE, R.; PASCUAL-MONTANO, A.; HARSHMAN,
(26) K. AND ESTEBAN, M. (2004) Microarray analysis reveals characteristic changes
(27) of host cell gene expression in response to attenuated modified vaccinia virus
(28) Ankara infection of human HeLa cells. J. Virol. 78 (11): 5820-34.
(29) GUERRA, S.; LOPEZ-FERNANDEZ, L.A.; PASCUAL-MONTANO, A.; MUNOZ, M.; HARSH-
(30) MAN, K. AND ESTEBAN, M. (2003) Cellular gene expression survey of vaccinia
(31) virus infection of human HeLa cells. J. Virol. 77 (11): 6493-506.
GUERRA, S.; LOPEZ-FERNANDEZ, L.A.; PASCUAL-MONTANO, A.; NAJERA, J.L.; ZABA-
(32) LLOS, A. AND ESTEBAN, M. (2006) Host response to the attenuated poxvirus
vector NYVAC: upregulation of apoptotic genes and NF-kappaB-responsive
genes in infected HeLa cells. J. Virol. 80 (2): 985-98.
GUERRA, S.; NAJERA, J.L.; GONZALEZ, J.M.; LOPEZ-FERNANDEZ, L.A.; CLIMENT, N.;
GATELL, J.M. ET AL. (2007) Distinct gene expression profiling after infection of
immature human monocyte-derived dendritic cells by the attenuated poxvi-
rus vectors MVA and NYVAC. J. Virol. 81 (16): 8707-21.
MESCHER, M.F.; AGARWAL, P.; CASEY, K.A.; HAMMERBECK, C.D.; XIAO, Z. AND
CURTSINGER, J.M. (2007) Molecular basis for checkpoints in the CD8 T cell
response: tolerance versus activation. Semin. Immunol. 19 (3): 153-61.
MESCHER, M.F.; CURTSINGER, J.M.; AGARWAL, P.; CASEY, K.A.; GERNER, M.; HAM-
MERBECK, C.D. ET AL. (2006) Signals required for programming effector and
memory development by CD8+ T cells. Immunol. Rev. 211: 81-92.
LU, B. (2006) The molecular mechanisms that control function and death of
effector CD4+ T cells. Immunol. Res. 36 (1-3): 275-82.
SUNDRUD, M.S. AND RAO, A. (2007) New twists of T cell fate: control of T cell
activation and tolerance by TGF-beta and NFAT. Curr. Opin. Immunol. 19
(3): 287-93.
ANEL, A.; BOSQUE, A.; NAVAL, J.; PINEIRO, A.; LARRAD, L.; ALAVA, M.A. ET AL.
(2007) Apo2L/TRAIL and immune regulation. Front. Biosci. 12:2074-84.
GOMEZ, C.E.; NAJERA, J.L.; JIMENEZ, E.P.; JIMENEZ, V.; WAGNER, R.; GRAF, M. ET
AL. (2006) Head-to-head comparison on the immunogenicity of two HIV/
AIDS vaccine candidates based on the attenuated poxvirus strains MVA and
NYVAC co-expressing in a single locus the HIV-1(BX08) gp120 and HIV-
1(IIIB) Gag-Pol-Nef proteins of clade B. Vaccine. 25 (15): 2863-85.
GOMEZ, C.E.; NAJERA, J.L.; JIMENEZ, V.; BIELER, K.; WILD, J.; KOSTIC, L.; ET AL.
(2007) Generation and immunogenicity of novel HIV/AIDS vaccine candida-

1077